Is HERON THERAPEUTICS, INC. /DE/ (HRTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 100.3% / 30% | 33.4% / 30% | 44.5% / 30% | 2.46% / 5% | ✗ NOT HALAL |
| DJIM | 100.3% / 33% | 33.4% / 33% | 44.5% / 33% | 2.46% / 5% | ✗ NOT HALAL |
| MSCI | 76.2% / 33% | 25.4% / 33% | 33.8% / 33% | 2.46% / 5% | ✗ NOT HALAL |
| S&P | 100.3% / 33% | 33.4% / 33% | 44.5% / 33% | 2.46% / 5% | ✗ NOT HALAL |
| FTSE | 76.2% / 33% | 25.4% / 33% | 33.8% / 50% | 2.46% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 72.6% | |
| Operating Margin | 0.1% | |
| Net Margin | -13.0% | |
| Return on Assets (ROA) | -0.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$28M |
| Free Cash Flow | -$28M |
| Total Debt | $141M |
| Debt-to-Equity | 981.2 |
| Current Ratio | 2.5 |
| Total Assets | $256M |
Price & Trading
| Last Close | $0.83 |
| 50-Day MA | $1.14 |
| 200-Day MA | $1.38 |
| Avg Volume | 1.7M |
| Beta | 1.3 |
|
52-Week Range
$0.75
| |
About HERON THERAPEUTICS, INC. /DE/ (HRTX)
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is HERON THERAPEUTICS, INC. /DE/ (HRTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), HERON THERAPEUTICS, INC. /DE/ is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is HERON THERAPEUTICS, INC. /DE/'s debt ratio?
HERON THERAPEUTICS, INC. /DE/'s debt ratio is 100.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 76.2%.
What are HERON THERAPEUTICS, INC. /DE/'s key financial metrics?
HERON THERAPEUTICS, INC. /DE/ has a market capitalization of $148M, and revenue of $155M. The company maintains a gross margin of 72.6% and a net margin of -13.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.